ClinicalTrials.gg
RecruitingNCT07264595Updated Sep 16, 2026

A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)

A Phase 1/2 interventional study of GS3-007a dry suspension and Placebo for GS3-007a dry suspension in Pediatric Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Study summary

This is a two-part clinical study for children with growth hormone deficiency. In the first part, participants will be randomly assigned to receive different doses of an oral treatment (GS3-007a dry suspension) or a placebo for 14 days. This part is double-blinded, meaning neither the participants nor the doctors will know who is receiving the treatment or placebo. The goal is to find a safe and well-tolerated dose.

In the second part, participants will be randomly assigned to receive either the selected dose of GS3-007a or another approved treatment for 52 weeks. This part is open-label, so everyone will know which treatment is being given. After that, all participants may continue taking GS3-007a for another 156 weeks in an extension phase to study long-term effects.

02

Conditions studied

  • Pediatric Growth Hormone Deficiency

Keywords

  • GS3-007a dry suspension
  • PGHD
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chronological age (CA) ≥3 years at Screening
  • Prepubertal girls or boys
  • Height at Screening lower than the reference height for normal children of the same chronological age and sex minus 2 standard deviations (-2 SD)
  • A confirmed diagnosis of growth hormone deficiency (GHD)
  • Having not been treated with any growth-promoting drugs
  • BA delayed by ≥6 months compared with the CA at Screening Subjects who meet all of the following criteria are eligible to enroll in the extension study (applicable for Part II extension period)
  • Subjects who have completed the 52-week treatment period of phase II
  • Subjects who do not permanently discontinue the Medicinal Product (IMP) during the 52-week treatment period of phase II

Exclusion criteria

Exclusion Criteria:

  • A highly allergic constitution
  • Suspected or confirmed total pituitary deficiency, including patients previously confirmed with deficiency of ≥2 pituitary hormones other than GH
  • Being confirmed with other chromosomal abnormalities or growth abnormalities affecting growth
  • Congenital skeletal dysplasia or serious spinal anomalies
  • Cognitive hypofunction, neurodevelopmental disorders, or psychiatric/psychological disorders that, in the investigator's opinion, may interfere with evaluation of study endpoints
  • Any abnormality that may affect growth or evaluation of the IMP
  • Screening magnetic resonance imaging (MRI) scan of the sellar region confirming prior or current intracranial tumor growth
  • Concurrent use of any medications that may affect growth or response to growth hormone therapy
  • Epiphyseal closure
  • (ECG) interval abnormal, with a history of QT/QTc interval prolonged
  • Hepatic function indicators abnormal at Screening Patients meeting any of the following criteria may not be enrolled in this extension study (applicable for Part II extension period)
  • Subjects with closed epiphyses
  • Any clinically significant abnormality that may affect growth or evaluation of the IMP
  • Known or suspected allergy to the IMP
  • Women with positive blood human chorionic gonadotropin (hCG) at the pre-treatment visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Placebo comparator
    Dose Level 1~ Dose Level 4

    dose level 1、dose level 2、dose level 3、dose level 4

    Drug: GS3-007a dry suspension · Drug: Placebo for GS3-007a dry suspension

  • Active comparator
    Cohort 1~ Cohort 3

    GS3-007a low dose , GS3-007a high dose , rhGH 0.033mg/kg

    Drug: GS3-007a dry suspension · Drug: rhGH injection

  • Experimental
    GS3-007a cohort

    GS3-007a optimal dose

    Drug: GS3-007a dry suspension

Interventions

  • DrugGS3-007a dry suspension

    GS3-007a

    Also known as: GS3-007a

  • DrugPlacebo for GS3-007a dry suspension

    Placebo for GS3-007a dry suspension

    Also known as: placebo

  • rhGH injection

    Also known as: rhGH

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: up to 21 days (Ib phase)

  2. Annualized height velocity (AHV) at Week 26 of treatment

    Time frame: 26 weeks (II phase)

  3. Number of Participants With TEAEs

    Time frame: up to 160 weeks (II phase extension)

Secondary outcomes

  1. Plasma Concentrations of GS3-007a and metabolite GS3-017. Due to Spare sampling time, there are no PK parameter

    Time frame: up to 7 days (Ib phase)

  2. Concentrations of serum growth hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3)

    Time frame: up to 14 days (Ib phase)

  3. AHVs at each evaluation point

    Time frame: 13 weeks, 39 weeks, 52 weeks (II phase)

  4. The standard deviation score (SDS) for an individual IGF-I measurement is calculated using the age-specific L, M, and S parameters, no minimum and maximum values, with higher scores indicating treatment improvement in PGHD

    Time frame: 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks (II phase)

  5. AHVs at each evaluation point

    Time frame: up to 156 weeks (II phase extension)

  6. The standard deviation score (SDS) for an individual height measurement is calculated using the age-specific L, M, and S parameters, no minimum and maximum values, with higher scores indicating treatment improvement in PGHD

    Time frame: up to 156 weeks (II phase extension)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Nov 2030, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartActual
Jan 18, 2026
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2030
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07264595
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Jan 18, 2026
Primary completion
Nov 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Sep 16, 2026

Study contacts

Lingli Sun, bachelor
Contact
sunlingli@genscigroup.com
+86 18006171657

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion